Safety, Tolerance and Pharmacokinetics Clinical Study of VC005 in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis

Inclusion Criteria:

healthy subject's study:

1. Healthy male or female subjects, aged 18-45 years (including critical values);

2. Body mass index (BMI) between 18 and 26kg/m2 (including critical values), with maleweight ≥ 50kg and female weight ≥ 45kg;

3. All women and men with fertility potential must be willing to use at least oneefficient method of contraception from the signing of the informed consent formuntil 3 months after the last administration of the study drug, as detailed inAppendix 5;

4. Voluntarily participate in the experiment and sign an informed consent form;

5. Subjects who are able to communicate well with the researcher and are willing andable to comply with all planned visits, treatment plans, laboratory tests, and otherresearch procedures

patient's study:

1. When informed consent is given, the age range is between 18 and 75 years (includingthe boundary value), regardless of gender;

2. Body mass index (BMI) between 18 and 26kg/m2 (including critical values), with maleweight ≥ 50kg and female weight ≥ 45kg;

3. Before administration, the diagnosis of mild to moderate atopic dermatitis should bemet: Overall Investigator Assessment (IGA) score of 2 to 3 points; Atopic dermatitis:total area of skin lesions 3% ≤ body surface area≤ 20%

4. Voluntarily sign an informed consent form (with a date), indicating that the subjecthas been informed of all relevant parts of the study;

5. All women and men with the possibility of childbirth must be willing to use at leastone efficient method of contraception from the signing of the informed consent formuntil 3 months after the last administration of the study drug, as detailed inAppendix 5;

6. Subjects who are willing and able to comply with planned visits and treatment plans,laboratory tests, and other research procedures

Exclusion Criteria:

healthy subject's study:

1. Suspected of being allergic to the study drug or any component of the study drug, orhaving an allergic constitution;

2. Those who have received the vaccine within 2 weeks before administration or plan toreceive the vaccine during the study period;

3. Screening for individuals who have undergone any surgery within the previous 6months;

4. Those who participated in blood donation within the first 3 months of screening andhad a blood donation volume of ≥ 400 mL, or received blood transfusion (excludingfemale physiological blood loss);

5. Female subjects of childbearing age had unprotected sexual intercourse with theiropposite sex partner within 14 days prior to screening;

6. Screening of clinical trial participants (including excipient groups) who haveparticipated in any drug or medical device within the first 3 months;

7. Pregnant and lactating women;

8. Patients with difficulty in blood collection or inability to tolerate venouspuncture, and those with a history of needle and blood fainting;

9. Those who smoke ≥ 5 cigarettes per day within the first 3 months of screening, andcannot stop using any tobacco products from the end of screening to enrollment andduring the trial period;

10. Those who have consumed more than 14 units of alcohol per week (1 unit of alcohol ≈ 360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine) within the first 3 monthsof screening, or who cannot abstain from alcohol during the trial period;

11. Other situations where the researcher determines that it is not suitable toparticipate in the experiment.

patient's study:

1. Suspected of being allergic to the study drug or any component of the study drug, orhaving an allergic constitution;

2. Those who have received the vaccine within 2 weeks before administration or plan toreceive the vaccine during the study period;

3. Screening for individuals who have undergone any surgery within the previous 6months;

4. Those who participated in blood donation within the first 3 months of screening andhad a blood donation volume of ≥ 400 mL, or received blood transfusion (excludingfemale physiological blood loss);

5. Screening of clinical trial participants (including excipient groups) who haveparticipated in any drug or medical device within the first 3 months;

6. Pregnant and lactating women;

7. Patients with difficulty in blood collection or inability to tolerate venouspuncture, and those with a history of needle and blood fainting;

8. Those who smoke ≥ 5 cigarettes per day within the first 3 months of screening, andcannot stop using any tobacco products from the end of screening to enrollment andduring the trial period;

9. Those who have consumed more than 14 units of alcohol per week (1 unit of alcohol ≈ 360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine) within the first 3 monthsof screening, or who cannot abstain from alcohol during the trial period;

10. Other situations where the researcher determines that it is not suitable toparticipate in the experiment.